Evidence map›Paper›PMID 33252885›Full record

ArticleThe New England journal of medicine2020

JAK Inhibition in the Aicardi-Goutières Syndrome. Reply.

Laura Adang, Raphaela Goldbach-Mansky, Adeline Vanderver

Abstract readLetterComment
In one paragraph

Article in The New England journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Nucleotide metabolism, leukodystrophies, and CNS pathology.Journal of inherited metabolic disease · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Laura AdangChildren's Hospital of Philadelphia, Philadelphia, PA.
Raphaela Goldbach-ManskyNational Institute of Allergy and Infectious Diseases, Bethesda, MD.
Adeline VanderverChildren's Hospital of Philadelphia, Philadelphia, PA vandervera@email.chop.edu.

Funding

Validation of the GMFC-MLDU54NS115052 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI Adeline Lucie Vanderver · 2019 to 2026
$14.3M
Clinical Outcomes in Aicardi Goutières SyndromeU01NS106845 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI VANDERVER, ADELINE LUCIE · 2019 to 2023
$7.5M
Clinical measures in Aicardi Goutieres SyndromeK23NS114113 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI ADANG, LAURA ANN · 2019 to 2023
$947k
NINDS NIH HHS K23 NS114113NINDS NIH HHS U01 NS106845NINDS NIH HHS U54 NS115052
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Autoimmune Diseases of the Nervous SystemNervous System MalformationsHumans

Identifiers

PMID33252885
PMCPMC11337977

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.